ONCOTRACK: The Liquid Biopsy blood test for cancer recurrence detection and monitoring
Dr. Avantika Batish is working as Director Strategy and Healthcare at International Health Emergency Learning and Preparedness. Also, guest faculty for MBA (HR) and MBA Healthcare Management at various B-Schools and is a soft skills trainer.
India is likely to have over 1.73 Million new cases of cancer and over 880,000 deaths due to the disease by 2020. Around 70% of all cancer patients approach the doctor when the disease has advanced, and the chances of cure are very low
To address and better manage the disease, Medgenome – India’s premier genomics based research and diagnostics company has launched “ONCOTRACK” which is a liquid biopsy based non-invasive screening test that is set to transform the way physicians in India can identify genetic alterations, interpret, assess and treat various forms of cancer. The test screens the samples by analyzing cell-free DNA that is isolated from the patients’ blood. Using high end sequencing technology, the screening process identifies specific gene mutations that are linked with Melanoma, Lung and Colon cancers. The test facilitates detection of mutation where there is difficulty of obtaining biopsy or in the event of a damaged biopsy material and nonavailability of tissue biopsy.
Oncotrack is a proven molecular tool after histopathology diagnosis and detecting molecular changes at baseline and at the time of relapse in lung and colon cancer for deciding the right treatment. The test has been validated in a scientific study, in academic collaboration with Tata Memorial Hospital.
Want to write for InnoHEALTH? send us your article at email@example.com